Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Abbott acquires Kos for $3.7bn in cash

Executive Summary

Abbott is paying $3.7bn in cash to buy all outstanding common shares of specialty drug company Kos Pharmaceuticals (focusing in the areas of cardiovascular, metabolic, and respiratory diseases) for $78 each, a 58% premium to market.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Payment Includes Cash
    • Full Acquisition
    • Includes Contract

Related Companies

UsernamePublicRestriction

Register